3D Cell Culture Market By Technology (Scaffold-based, Scaffold-free, Bioreactors), By Application (Cancer, Tissue Engineering & Immunohistochemistry, Drug Development, Stem Cell Research, Others), By End-User (Biotechnology and Pharmaceutical Industries, Research Laboratories and Institutes, Hospitals and Diagnostic Centers, Others), By Geography, Size, Share, Trends, Global Growth Forecast, 2021-2030

Published On: May-2022 Base Year: 2021 No Of Pages: 135 Historical Data: 2017 - 2020 Formats: PDF Report ID: 82280429

Industry Report and Statistics

The global 3d cell culture market will witness a robust CAGR of 16.3%, valued at $1.66 billion in 2021, expected to appreciate and reach $6.46 billion by 2030, confirms Strategic Market Research. North America surpassed the global industry in 2020, with a revenue share of more than 43%. Cell culture is described as various laboratory techniques that allow eukaryotic or prokaryotic cells to develop in physiological settings. It was first used to research tissue growth and maturation, virus biology and vaccine creation, the function of genes in illness and health, and large-scale hybrid cell lines to manufacture biopharmaceuticals in the early twentieth century. Cultured cells have as many practical uses as cell types that can be produced in vitro. Cell culture is most typically used in clinical settings to create model systems for studying basic cell biology, replicating disease mechanisms, or testing the toxicity of new therapeutic molecules. The ability to modify genes and molecular pathways is one of the benefits of employing cell culture for these applications. Furthermore, the homogeneity of clonal cell populations or specific cell types and well-defined culture systems eliminates interfering genetic or environmental variables, allowing for high reproducibility and consistency in data generation that is impossible to guarantee when studying whole organ systems. Curi Bio's platform solutions facilitate faster development of therapies by combining human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics. The $6 million Series A funding round, led by Dynamk Capital, will help the company to build and verify its technology, demonstrating the need for predictive and mature human stem cell platforms to bridge the gap between preclinical and clinical outcomes. 3D cell culture is an in-vitro approach that involves creating an artificial environment and then allowing biological cells to develop, grow, or communicate using vascular endothelial growth factor and epidermal growth factor receptors with their environments in all three dimensions. A surge in cancer patients globally, rising investments, and growing incidence of infectious diseases primarily propel the market.

Key Market Drivers - Rise in Infectious Diseases, Increasing Investments, and Expanding Emphasis on Healthcare Quality

The global 3D cell culture market is being driven largely by its plethora of applications in drug screening through high-throughput screening, regenerative medicine, drug repositioning while taking care of pharmacology and toxicology, stem cell treatments, 3D cell culture cancer research, and cell biology. According to a research study, differences in T-DM1 drug action in 3D spheroids or aggregates could be attributed to tumour heterogeneity and less effective T-DM1 internalization, which is not evident in 2D cell culture models. In future drug response and resistance research, 3D cell culture experiments will provide biologically appropriate models for assessing drug screening activities in tumour tissue. Furthermore, the sector benefits from the increasing use of 3D cell culture models as an alternative approach for in vivo testing, research and development of extended cell culture systems, and increased demand for organ transplantation.

In addition to this, the rise in infectious illnesses has prompted the development of antiviral medications, bioreactors, cell-based treatments through primary cell culture and animal tissue culture, and vaccinations employing cell culture techniques. According to the CDC, TB bacteria afflicted 1.7 billion individuals or roughly 23% of the world's population. TB is the principal cause of fatality worldwide, claiming 1.5 million lives each year. The desire for cell-based vaccinations has grown since the procedure generates vaccines in the lowest time and is not restricted by the choice of vaccine viruses suited for eggs' development.

Moreover, the expanding emphasis on healthcare quality, the growing concern about the rise of microfluidics-based 3D cell culture methods, increasing investment for technical advancement, and the launch of new products contribute to the market's overall expansion. To stimulate the growth of its biopharmaceutical contract development and manufacturing business, FUJIFILM Corporation is investing more than $2 billion in a new large-scale cell culture production site in the United States (CDMO). According to the findings of the Centers for Medicare & Medicaid Services, the federal government's healthcare spending climbed 36.0 % in 2020, compared to 5.9% in 2019. The COVID-19 pandemic contributed significantly to this sudden upsurge in growth. Hospital spending rose to 6.4 % to $1,270.1 billion in 2020, faster than the 6.3 % growth in 2019.

Market Restraints - Higher Cost of Technology, Availability of Substitutes, and Lack of Trained Professionals

Lack of skilled professionals, availability of substitutes such as 2D cell culture, and higher cost of the technologies will hamper the growth of the 3D cell culture industry.

Opportunities: - Rising Awareness, Increasing Investment and R&D

Recent developments in neuromuscular-reproducing in-vitro systems, enabled by 3D cell-culture methods, have improved reliability. Furthermore, advancements in 3D cell culture for recreating the whole spinal-locomotion circuit and neurodegenerative processes are expected to generate a good potential for global industry expansion.

Increasing awareness, an increase in the funding in stem cell research, and the expanding use of 3D cell culture in cancer therapy, cell-based biosensors, 3D cell culture assays for in vitro (3D cell culture organoid) evaluation of anti-cancer drugs, 4D cell culture might all contribute to a market spike throughout the review period. The Hon Greg Hunt, the Federal Minister for Health and Aged Care, allocated funding of $18.7 million for the 2020 Stem Cell Mission, which is focused on developing and delivering novel, safe, and effective stem cell treatments to enhance health outcomes. The University of Sydney had been given $6.3 million for three studies that will treat adult blindness and chronic heart disease and help to enhance judgments about stem cell interventions.

3d cell culture market by technology 2020-2030

Market Analysis Of Different Segments Covered in the Report

Based on Technology

Scaffold-based
Hydrogels
Polymeric Scaffolds
Micro-patterned Surface Microplates
Nanofiber-based Scaffolds
Scaffold-free
Hanging Drop Microplates
Microfluidic 3D Cell Culture
Spheroid Microplates with ULA coating
Magnetic Levitation & 3D Bioprinting
Bioreactors

Based on Application

Cancer
Tissue Engineering & Immunohistochemistry
Drug Development
Stem Cell Research
Others

Based on End-User

Biotechnology and Pharmaceutical Industries
Research Laboratories and Institutes
Hospitals and Diagnostic Centers
Others

Regional Coverage Analysis

North America

USA
Canada
Mexico
Rest of North America

Europe

Germany
UK
France
Switzerland
Russia
Rest of Europe

Asia-Pacific

India
China
Japan
Rest of Asia pacific

LAMEA

Brazil
Argentina
UAE
Rest of LAMEA

3d cell culture market by end user 2020-2030

Technology Analysis & Insights

Scaffold-based technology had the highest revenue share of more than 68.96% in 2020. In 3-dimensional cell culture-based research, using hydrogels as scaffolds allows the integration of complex biochemical and mechanical signals that mimic the natural extracellular matrix. Furthermore, the increased popularity and awareness of nanotechnology in biomedical research is expected to offer future growth opportunities for nanofiber-based scaffolds, consequently increasing customer preference for scaffold-based technology. The National Institutes of Health announced an investment of $445 million in nanomedicine in 2020. The National Nanotechnology Initiative got more than $1.7 billion in funding in 2021. As a result, it will further augment the growth of the 3D cell culture scaffold market.

Application Analysis & Insights

In 2020, the Cancer sector led the market, accounting for 24.56% of total revenue, and is projected to grow at a CAGR of 15.4%. R&D in this industry is driven by using spheroids as model systems to develop anti-cancer treatments. The National Cancer Institute estimated that there were 16.9 million cancer survivors in the United States in 2020, and by 2030, the number of cancer survivors is expected to reach 22.2 million. Moreover, using 3-dimensional cellular models to study cancer in preclinical testing and screening is expected to increase the revenue generation of this segment. A research article published in January 2021 announced the creation of polysaccharide hydrogel-based 3D printed tumour models can be utilized for high throughput screening of anti-cancer medications. Moreover, from 2021 to 2030, the stem cell research segment is predicted to foster a robust growth rate.

End-user Analysis & Insights

In 2020, the biotechnology and pharmaceutical industries category produced the highest revenue share of more than 46%. Compared to 2D cell culture, different types of 3D cell culture have benefits in terms of appropriate oxygen and nutritional gradients, non-uniform exposure of cells within a spheroid to a drug, and realistic cell-to-cell interactions. Because of these qualities, 3D cell cultures are more suited for drug discovery and development, which drives demand.

Region Analysis & Insights

North America dominated the global 3D cell culture market in 2020, with more than 43 % revenue share. The region will lead throughout the forecasted period because of private and state financial support for developing advanced 3D cell culture models, high healthcare spending, and the increased number of universities and research organizations investigating various stem cell-based approaches. Blackbird Ventures led a $25 million Series B fundraising round for Inventia Life Science, a global leader in advanced 3D cell cultures for research and clinical uses. Inventia also announced the start of its operations in the United States. Inventia intends to use this Series B round of funding to commercialize its RASTRUM 3D cell culture technology globally and expand its team from 36 to 150 workers by 2024. It intends to establish a substantial presence in the United States, where the biomedical research and drug discovery sectors are valued at more than $40 billion. The Series B round raises Inventia's total funding to $32 million. However, Asia Pacific will witness the fastest regional market from 2021 to 2030 due to increased investments by various multinational corporations in the region's rising economies.

3D Cell Culture Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
Market size value in 2021	USD 1.66 billion
Revenue forecast in 2030	USD 6.47 billion
Growth rate	CAGR of 16.3 %
The base year for estimation	2020
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By Technology, By Application, By End Users, By Region.
By Technology	Scaffold-based, Scaffold-free, Bioreactors
By Application	Cancer, Tissue Engineering & Immunohistochemistry, Drug Development, Stem Cell Research, Others
By End-User	Biotechnology and Pharmaceutical Industries, Research Laboratories and Institutes, Hospitals and Diagnostic Centers, Others
By Region	Europe, Asia Pacific, North America, and LAMEA
Country Scope	US, Brazil, Canada, Germany, UK, France, China, Japan, India etc.
Company Usability Profiles	Merck KGaA, Thermo Fisher Scientific, Inc., PromoCell GmbH, Greiner Bio One International GmbH, Corning, Inc., 3D Biomatrix, Lonza, Avantor Performance Materials, LLC, Tecan Trading AG, 3D Biotek LLC

Global 3D Cell Culture Market Competitive Landscape Analysis

The competitive landscape analysis gives an overview of some prominent players operating in the market. Product innovation and continued R&D operations to create sophisticated technologies have assisted the industry growth. In the target industry, some of the leading 3D cell culture companies are:

Merck KGaA
Thermo Fisher Scientific, Inc.
PromoCell GmbH
Greiner Bio One International GmbH
Corning, Inc.
3D Biomatrix
Lonza
Avantor Performance Materials, LLC
Tecan Trading AG
3D Biotek LLC
Global Cell Solutions, Inc.
InSphero

3d cell culture market by region 2020-2030

Recent Developments:

On 15th December 2021, CellPort Software, a SaaS firm that digitizes cell development and production workflows, joined the Tetra Partner Network (TPN) to speed the delivery of cell-based medicines, according to TetraScience, the R&D Data Cloud company. CellPort is dedicated for the creation of scientific data liquidity. TetraScience's platform conveniently connects laboratory items to CellPort's software via this agreement, allowing users to swiftly construct innovative, new processes and acquire critical insights into cell lines.

On 11th January 2021, Adocia created a novel hydrogel to host and protect pancreatic cell implants. This hydrogel scaffold containing pancreatic cells has the potential to restore glycemic control without the need for insulin injections or immunosuppressive medications. An academic partnership has been created with Pr. Pattou's Inserm Team, the global leader in islet transplant, to develop this product in animal models and, eventually, in humans.

On 8th December 2020, eNUVIO announced the launch of market's first entirely reusable 3D cell culture microplate. The introduction of eNUVIO's entirely reusable EB-Plate in the market comes at an ideal time; since there is a significant demand for 3D cell culture microplates. Traditional plastic plates are now in limited supply, and the zero-waste campaign is gaining traction in laboratories. Furthermore, the manufacturers claim that the new plates pay for themselves after 5-8 uses and may be reused many times more.

Various 3D Cell Culture Commercial Products that the Market Leaders are Manufacturing

Name	Feature	Key Player
Corning CoolCell	In conjunction with a -80°C freezer, the Corning CoolCell will deliver alcohol-free freezing at a rate of -1°C/minute, appropriate for the cryopreservation of most cells and cell lines.	Corning
Gibco FreeStyle F17	A chemically defined, protein-free, serum-free media designed to enable the suspension growth and transfection of HEK293 cells. Before usage, 4–8 mM L-glutamine or GlutaMAX supplementation is recommended.	Thermo Fisher Scientific, Inc.
GrowDex	A bio-friendly hydrogel derived from birch and produced from properly maintained forests, GrowDex is a ready-to-use hydrogel that replicates the extracellular matrix (ECM), promoting continuous cell growth and differentiation.	UPM Biomedicals

Frequently Asked Question About This Report

b: Merck KGaA, Thermo Fisher Scientific, Inc., PromoCell GmbH, Greiner Bio-One International GmbH, Corning, Inc., and 3D Biomatrix are some of the leading companies.

b: The global 3d cell culture market is expected to grow at a compound annual growth rate (CAGR) of 16.3% from 2021 to 2030 to reach $6.46 Billion by 2030.

b: Hike in the number of cancer patients globally, rising investments, and growing incidence of infectious diseases are primarily driving the market.

b: The global 3d cell culture market size was $1.66 Billion in 2021 and is predicted to reach $6.46 Billion by 2030 with a CAGR of 16.3%.

Sources

https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html

https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-u-s-a/

https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet

https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/180-million-in-medical-research-to-improve-the-lives-of-australians

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464102/

https://cancercontrol.cancer.gov/ocs/statistics